Abstract
Objective
To describe the methodology and to present the baseline findings of the Attention-deficit/hyperactivity Disorder Observational Research in Europe (ADORE) study, the primary objective of which is to describe the relationship between treatment regimen prescribed and quality of life of children with ADHD in actual practice.
Methods
In this 2-year prospective observational study, data on diagnosis, prescribed treatment and outcomes of ADHD were collected at seven time points by paediatricians and child psychiatrists on 1,573 children recruited in 10 European countries. The data presented here from the 1,478 patients included in the analyses describe the baseline condition, initial treatment regimen prescribed and quality of life of families with children with ADHD.
Results
Patients had a mean age of 9.0 years (SD 2.5) and 84% were male. Physicians diagnoses were made using DSM-IV (43 %), ICD-10 (32%) and both DSM-IV and ICD-10 (12 %). Mean age of awareness of a problem was 5.1 years, suggesting an average delay of approximately 4 years between awareness and diagnosis of ADHD. Baseline ADHD rating scale scores (physicianrated) indicated moderate to severe ADHD. Parent-rated SDQ scores were in agreement and suggested significant levels of co-existing problems. CGI-S, CGAS and CHIPCE scores also indicated significant impairment. Patients were offered the following treatments after the initial assessment: pharmacotherapy (25 %), psychotherapy (19 %), combination of pharmacotherapy and psychotherapy (25 %), other therapy (10 %) and no treatment (21 %).
Conclusion
The ADORE study shows that ADHD is similarly recognised across 10 European countries and that the children are significantly impaired across a wide range of domains. In this respect, they resemble children described in previous ADHD samples.
Similar content being viewed by others
Abbreviations
- ADHD:
-
Attention-Deficit/Hyperactivity Disorder
- ADORE:
-
Attention-deficit/hyperactivity Disorder Observational Research in Europe
- ADHD-RS-IV:
-
ADHD Rating Scale-IV
- CD:
-
Conduct Disorder
- CHIP-CE:
-
Child Health and Illness Profile – Child Edition
- CGAS:
-
Children's Global Assessment Scale
- CGI-S:
-
Clinical Global Impression-Severity scale
- FSI:
-
Family Strain Index
- HD:
-
Hyperkinetic Disorder
- HRQoL:
-
Health-Related Quality of Life
- ODD:
-
Oppositional Defiant Disorder
- SDQ:
-
Strengths and Difficulties Questionnaire
References
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, fourth edition. American Psychiatric Association, Washington
Anastopoulos AD, Guevremont DC, Shelton TL, DuPaul GJ (1992) Parenting stress among families of children with attention deficit hyperactivity disorder. J Abn Child Psychol 20:503–520
Becker A, Steinhausen HC, Baldursson G, Dalsgaard S, Lorenzo MJ, Ralston SJ, Döpfner M, Rothenberger A, and the ADORE study group (2006) Psychopathological screening of children with ADHD: Strengths and Difficulties Questionnaire in a pan-European study. Eur Child Adolesc Psychiatry 15(Suppl 1):56–62
Biederman J, Newcorn J, Sprich S (1991) Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148:564–577
Brown TE (2005) Attention-deficit disorders and comorbidities in children, adolescents and adults. American Psychiatric Press Inc., Washington
Corkum P, Tannock R, Moldofsky H (1998) Sleep disturbances in children with attention-deficit/hyperactivity disorder. J Am Acad Child and Adolescent Psychiatry 37:637–646
Döpfner M, Steinhausen HC, Coghill D, Dalsgaard S, Poole L, Ralston SJ, Rothenberger A and the ADORE study group (2006) Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study. Eur Child Adolesc Psychiatry 15(Suppl 1):46–55
DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998) ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. Guilford Press, New York
Efron D, Jarman FC, Barker MJ (1998) Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. J Paediatr Child Health 34:288–292
Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I (2005) Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 116:e364–e369
Faraone SV, Biederman J, Milberger S (1995) How reliable are maternal reports of their children's psychopathology? One-year recall of psychiatric diagnoses of ADHD children. J Am Acad Child Adolesc Psychiatry 34:1001–1008
Faraone SV, Tsuang MT (2001) Adult attention deficit hyperactivity disorder. Curr Psychiatry Rep 3:129–130
Gillberg C (1998) Hyperactivity, inattention and motor control problems: prevalence, comorbidity and background factors. Folia Phoniatrica et Logopaedica 50:107–117
Goodman R (1997) The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry 38:581–586
Goodman R (2001) Psychometric properties of the strengths and difficulties questionnaire. J Am Acad Child Adolescent Psychiatry 40:1337–1345
Guy W (1976) Subject's Treatment Emergent Symptom Scale. In: Guy W (ed) Assessment Manual for Psychopharmacology. Washington, US Government Printing Office, pp 347–350
Jensen PS, Martin D, Cantwell DP (1997) Comorbidity in ADHD: implications for research, practice and DSM-V. J Am Acad Child Adolesc Psychiatry 36:1065–1079
Johnston C, Mash EJ (2001) Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 4:183–207
Kirov R, Kinkelbur J, Heipke S, Kostanecka-Endress T, Westhoff M, Cohrs S, Rüther E, Hajak G, Banaschewski T, Rothenberger A (2004) Is there a specific polysomnographic sleep pattern in children with attention deficit/hyperactivity disorder? J Sleep Res 13:87–93
Kirov R, Pillar G, Rothenberger A (2004) REM-sleep changes in children with attention-deficit/hyperactivity disorder: methodologic and neurobiologic considerations. Sleep 27:1215 [letter]
Klassen AF, Miller A, Fine S (2004) Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114:e541–e547
Matza LS, Paramore C, Prasad M (2005) A review of the economic burden of ADHD. Cost Effectiveness and Resource Allocation 3:5
Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D, Spencer T, Newcorn JH, Kratochvil CJ (2004) The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Devel Behav Pediatr 25:166–174
Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention-deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896–1901
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T and the Atomexetine ADHD Study Group (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83
MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attentiondeficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073–1086
Owens JA (2005) The ADHD and sleep conundrum: a review. J Devel Behav Pediatr 26:312–322
Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK,Allen AJ (2004) Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Devel Behav Pediatr 25:264–271
Pliszka SR (2000) Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 9:525–540
Ralston SJ, Lorenzo MJ (2004) ADORE – Attention-Deficit Hyperactivity Disorder Observational Research in Europe. Eur Child Adolesc Psychiatry 13(Suppl 1):36–42
Riley AW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G and the ADORE study group (2006) Validity of the health-related quality of life assessment in the ADORE study: parent report form of the CHIP-Child Edition. Eur J Child Adolesc Psychiatry 15(Suppl 1):63–71
Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF (2004) The parent report form of the CHIP-Child Edition: reliability and validity. Med Care 42:210–220
Riley AW, Robertson JA, Forrest CB, Green BF, Rebok G, Starfield B (2001) Technical Manual for the Child Health and Illness Profile – Child Edition (CHIP-CE) Parent and Child Report Forms, 1.0 edn, Johns Hopkins University, Baltimore
Riley AW, Spiel G, Coghill D, Döpfner M, Falissard B, Lorenzo MJ, Preuss U, Ralston SJ and the ADORE study group (2006) The Family Strain Index (FSI). Reliability, validity and factor structure of a brief questionnaire for families of children with ADHD. Eur Child Adolesc Psychiatry 15(Suppl 1):72–78
Rothenberger A, Woerner W (2004) Strengths and Difficulties Questionnaire (SDQ)–evaluations and applications. Eur Child Adolesc Psychiatry 13(Suppl 2):1–2
Rutter M (1967) A children's behaviour questionnaire for completion by teachers: preliminary findings. J Child Psychol Psychiatry 8:1–11
Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S (1983) A children's global assessment scale (CGAS). Arch Gen Psychiatry 40:1228–1231
Stein MA (1999) Unravelling sleep problems in treated and untreated children with ADHD. J Child Adolesc Psychopharmacol 9:157–168
Steinhausen HC, Nøvick TS, Baldursson G, Curatolo P, Lorenzo MJ, Pereira RR, Ralston SJ, Rothenberger A and the ADORE study group (2006) Co-existing psychiatric problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry 15(Suppl 1):25–29
Taylor E (1998) Clinical foundations of hyperactivity research. Behav Brain Res 94:11–24
Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A, Taylor E, Dopfner M, Sergeant J,Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A,Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):7–30
World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines WHO, Geneva, Switzerland
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
* Members of the Adore Study Group G Baldursson, D Coghill, P Curatolo, S Dalsgaard, M Döpfner, B Falissard, A Hervas, MF Le Heuzey, TS Nøvik, RR Pereira, U Preuss, S Ralston, P Rasmussen, AW Riley, A Rothenberger, G Spiel, HC Steinhausen, L Vlasveld
**Employed by Eli Lilly and Company at the time the research was performed
Rights and permissions
About this article
Cite this article
Preuss, U., Ralston**, S.J., Baldursson, G. et al. Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry 15 (Suppl 1), i4–i14 (2006). https://doi.org/10.1007/s00787-006-1002-0
Issue Date:
DOI: https://doi.org/10.1007/s00787-006-1002-0